HER2-Targeted Antibody–Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget’s Disease Models: In Vivo and Immunohistochemical Analyses

SIMPLE SUMMARY: The prognosis for advanced Extramammary Paget’s disease (EMPD) is almost always poor. HER2-targeted antibody–drug conjugates (ADCs) such as trastuzumab emtansine and trastuzumab deruxtecan have proven to be effective against HER2-positive breast cancers; however, no studies have addr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokuchi, Keiko, Maeda, Takuya, Kitamura, Shinya, Yanagi, Teruki, Ujiie, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322551/
https://www.ncbi.nlm.nih.gov/pubmed/35884581
http://dx.doi.org/10.3390/cancers14143519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322551/
https://www.ncbi.nlm.nih.gov/pubmed/35884581
http://dx.doi.org/10.3390/cancers14143519

Ejemplares similares